QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
Public ClinicalTrials.gov record NCT03563157. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
NANT Colorectal Cancer (CRC) Vaccine: A Phase 1b/2 Trial of the NANT CRC Vaccine vs Regorafenib in Subjects With Metastatic CRC Who Have Been Previously Treated With Standard-of-Care Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
QUILT 3.071 NANT Colorectal Cancer (CRC) Vaccine: This is a Phase 1b/2 study investigating the effect of NANT CRC vaccine vs regorafenib in subjects with CRC who were previously treated with SOC.
Study identification
- NCT ID
- NCT03563157
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 2 participants
Conditions and interventions
Conditions
Interventions
- Aldoxorubicin Hydrochloride Biological
- ALT-803 Biological
- ETBX-011 Biological
- ETBX-021 Biological
- ETBX-051 Biological
- ETBX-061 Biological
- GI-4000 Biological
- GI-6207 Biological
- GI-6301 Biological
- haNK Biological
- Avelumab Drug
- Capecitabine Drug
- Cetuximab Drug
- Cyclophosphamide Drug
- 5-Fluorouracil Drug
- Leucovorin Drug
- Nab-paclitaxel Drug
- Oxaliplatin Drug
- Regorafenib Drug
- SBRT Procedure
Biological · Drug · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 27, 2018
- Primary completion
- Apr 20, 2019
- Completion
- Aug 20, 2019
- Last update posted
- Dec 10, 2024
2018 – 2019
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Chan Soon-Shiong Institute for Medicine | El Segundo | California | 90245 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03563157, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 10, 2024 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03563157 live on ClinicalTrials.gov.